Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acasti Pharma (ACST)

Acasti Pharma (ACST)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 164,426
  • Shares Outstanding, K 85,195
  • Annual Sales, $ 0 K
  • Annual Income, $ -39,290 K
  • 60-Month Beta 1.36
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 56.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.08
  • Number of Estimates 3
  • High Estimate -0.07
  • Low Estimate -0.09
  • Prior Year -0.20
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.78 +2.81%
on 10/29/19
2.23 -17.94%
on 10/15/19
-0.34 (-15.67%)
since 10/11/19
3-Month
1.54 +18.83%
on 08/28/19
2.32 -21.12%
on 09/09/19
-0.26 (-12.44%)
since 08/09/19
52-Week
0.60 +205.00%
on 11/27/18
2.95 -37.97%
on 07/30/19
+0.84 (+84.85%)
since 11/09/18

Most Recent Stories

More News
Acasti Pharma Announces Publication of CaPre Pharmacokinetics Study in a Leading Peer-Reviewed Journal

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R)...

ACST : 1.83 (-5.18%)
ACST.VN : 2.450 (-3.54%)
Acasti Pharma Schedules Second Quarter Fiscal 2020 Conference Call

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 1.83 (-5.18%)
ACST.VN : 2.450 (-3.54%)
Acasti Pharma Partners with Aker BioMarine to Supply Krill Oil for CaPre(R)

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R)...

ACST : 1.83 (-5.18%)
ACST.VN : 2.450 (-3.54%)
Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R)...

ACST : 1.83 (-5.18%)
ACST.VN : 2.450 (-3.54%)
Biotechs Endeavour to Increase Access to Cancer Treatments

Cancer is the second leading cause of death globally and was responsible for approximately 9.6 million deaths in 2018, according to the World Health Organization (WHO). Statistically, cancer is the cause...

ONPH : 0.0302 (-2.58%)
AGEN : 3.90 (+9.24%)
INO : 2.45 (-2.78%)
GERN : 1.48 (unch)
ACST : 1.83 (-5.18%)
Acasti Pharma Announces Additional Phase 3 Milestones Reached, and Remains on Track to Report Topline Results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020

Nearly 80% of randomized patients have completed the studies

ACST : 1.83 (-5.18%)
ACST.VN : 2.450 (-3.54%)
Acasti Pharma Receives Funding from the Government of Canada to Expand Production Capacity

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST) a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 1.83 (-5.18%)
ACST.VN : 2.450 (-3.54%)
Acasti Pharma to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 9th

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R)...

ACST : 1.83 (-5.18%)
ACST.VN : 2.450 (-3.54%)
Acasti Pharma Announces the Election of Its Directors, Amendments to Its Stock Option and Equity Incentive Plans and Other Related Matters Approved at Its AGM

Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 1.83 (-5.18%)
ACST.VN : 2.450 (-3.54%)
Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2020

Achieved 100% Patient Randomization in both TRILOGY trials

ACST : 1.83 (-5.18%)
ACST.VN : 2.450 (-3.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft.

See More Share

Trade ACST with:

Business Summary

Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R)...

See More

Key Turning Points

2nd Resistance Point 1.98
1st Resistance Point 1.91
Last Price 1.83
1st Support Level 1.79
2nd Support Level 1.74

See More

52-Week High 2.95
Fibonacci 61.8% 2.05
Last Price 1.83
Fibonacci 50% 1.78
Fibonacci 38.2% 1.50
52-Week Low 0.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar